Only One in Six Enterprises Treats Indirect Tax as a Standing Board Item

Vertex released its 2026 CompOps Index showing that enterprises with indirect tax as a standing board item are four times less likely to have errors identified externally and nearly twice as likely to respond to tax-authority notices within five business days. Only 16% of enterprises currently have indirect tax as a standing board item, while 43% only discuss it when problems arise. The study also found that enterprises with board-level tax discussions are more likely to deploy AI autonomously in tax workflows (54% vs. 21%) and maintain better regulatory compliance.

11/11/2026, 8:00 AM • GlobeNewswire

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.

11/08/2026, 4:32 PM • The Motley Fool

Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.

11/07/2026, 11:15 AM • The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.

11/07/2026, 9:37 AM • The Motley Fool

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.

11/03/2026, 1:00 PM • GlobeNewswire

Breakfast News: Apple’s Record Quarter Has a Catch

Apple reported record Q4 revenue of $114.5B with 12% growth and strong iPhone/Mac sales, but shares fell as gross margins are expected to compress to 45.5% due to unprecedented memory chip costs. Meanwhile, Palantir beat earnings but fell on slowing commercial contract growth, BBB Foods swung to profitability and surged 6%, and Vertex met expectations with modest gains. Election Day historically shows weak correlation to market returns, with the real drivers being company earnings and valuations.

11/03/2026, 7:30 AM • The Motley Fool

Breakfast News: We’re Right There With You

The Nasdaq-100 fell nearly 5% on Friday, marking its third 10% correction this year, though it has nearly doubled over three years. The article advises investors to stay invested during market volatility through strategies like dollar-cost averaging and diversification. Key earnings this week include Apple, Shopify, AMD, and Berkshire Hathaway. Kiniksa Pharmaceuticals' heart drug Arcalyst is projected to become a blockbuster with $1B+ sales. Investors should focus on long-term plans rather than election-driven trading.

11/02/2026, 7:30 AM • The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen and Vertex Pharmaceuticals present contrasting investment profiles: Amgen generates significantly larger quarterly revenues ($8.1B-$10.1B) with moderate fluctuations and expects ~3% growth in 2026, while Vertex shows steady, gradual revenue growth ($2.8B-$3.3B) driven by its cystic fibrosis focus and the promising Alyftrek treatment. Vertex's expansion into autoimmune diseases with Povetacicept could reach $4-7B in peak annual sales, while Amgen's scale and six $1B+ drug franchises provide acquisition capacity despite slower growth.

10/27/2026, 3:25 PM • The Motley Fool

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?

VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.

10/27/2026, 10:43 AM • The Motley Fool

I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move

Despite concerns about elevated valuations and potential market corrections, the author argues investors shouldn't worry about crashes if they hold quality stocks long-term. The S&P 500 has gained 100% over three years, but the Shiller CAPE ratio suggests stocks are expensive. The author recommends holding quality companies and buying dips rather than timing the market, citing historical data showing recovery after downturns.

10/26/2026, 4:45 AM • The Motley Fool

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH), which concentrates on 25 biotech companies with higher volatility, and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), which diversifies across 61 healthcare companies. While BBH showed stronger 1-year returns (38.3% vs 25.7%), RSPH is recommended for long-term investors due to lower concentration risk, broader diversification, and higher dividend yield, despite slightly higher expense ratios.

10/25/2026, 5:20 AM • The Motley Fool

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Vertex Pharmaceuticals is diversifying beyond its dominant cystic fibrosis franchise, which currently accounts for 96% of product sales. The company is expanding into new therapeutic areas through promising pipeline candidates including pain relief drug Journavx, gene-editing therapy Casgevy (with CRISPR Therapeutics), kidney disease therapy inaxaplin, and recent acquisitions like Crinetics Pharmaceuticals ($10 billion) for endocrine disease treatments. With Q2 revenue of $3.33 billion (up 12% YoY) and raised full-year guidance, Vertex expects $500 million+ in 2026 sales from new products.

10/24/2026, 3:09 PM • The Motley Fool

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?

The article compares two healthcare sector ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on 27 pharmaceutical companies, and iShares Biotechnology ETF (IBB), which covers 243 biotech stocks. IBB has a lower expense ratio (0.44% vs 0.58%) and outperformed over the past year (37.7% vs 33.9% return), but PJP offers higher dividend yield (0.92% vs 0.16%) and lower volatility. The choice depends on investor risk tolerance and portfolio goals.

10/23/2026, 1:41 AM • The Motley Fool

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

10/22/2026, 5:30 AM • The Motley Fool

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

10/19/2026, 4:10 AM • The Motley Fool